A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

NCT04436640 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

508

Enrollment

INDUSTRY

Sponsor class

Conditions

Axial Spondyloarthritis
Ankylosing Spondylitis
r-axSpa
Nr-axSpa

Interventions

DRUG: Bimekizumab

Sponsor

UCB Biopharma SRL